Objective-To investigate the apparent increased risk of severe hypoglycaemia associated with use of human insulin by comparing the pattern of symptoms of hypoglycaemia with human insulin and porcine insulin.
Introduction
Decreased awareness of hvpoglycaemia in diabetic patients transferred to treatment with human insulin was first reported in 1987 on the basis of retrospective questionnaire surveys. 2 Subsequently, in a randomised double blind crossover trial, hunger and sweating were found to be significantly less common initial symptoms of hypoglycaemia when human insulin, as compared with porcine insulin, was being taken. 3 Hunger and sweating were considered to be "warning symptoms" -that is, symptoms likely to alert the patients to their incipient hypoglycaemia and allow then to take evasive action. Conversely, a group of neuroglycopenic symptoms, including lack of concentration and confusion, were seen significantly more often as the initial symptoms of hypoglycaemia with human insulin. The authors suggested that the congnitive impairment associated with these symptoms could result in patients failing to take appropriate steps to avoid the development of hypoglycaemia. Their study was criticised, however, because the results were deemed to depend on the allocation of symptoms into the categories "warning" and "neuroglycopenic. "4 In the hospital based case-control study reported in this issue (p 617) we found an increased rate of presentation for hypoglycaemia in patients transferred to human insulin.5 In the present paper we report a randomised double blind study carried out to investigate whether transfer to human insulin leads to patients experiencing hypoglycaemia in a way that may hinder appropriate response.
Patients and methods

PATIENTS
Forty four outpatients were selected who met the following criteria: had insulin dependent diabetes mellitus confirmed by a C peptide concentration <0 03 nmol/l; were receiving treatment with fast acting soluble insulin and long acting protamine insulin; were performing routine multiple daily fingerstick blood glucose self measurements before the study; and had stable glycaemic control with about one mild hypoglycaemic episode a week during the preceding two months.
At the time of entry into the study 18 patients were being treated with human insulin and 26 with porcine insulin. Thirty one patients were taking four daily injections with a pen injector before meals. The remaining patients were taking two daily injections. Twelve patients had experienced recurrent hypoglycaemic coma, defined as two or more episodes during the preceding three years. Written informed consent was obtained from each participant, and the trial was approved by the ethical committee of the medical faculty of the University of Berne.
STUDY DESIGN
Twenty two of the patients were selected by using random number tables initially to receive human insulin; the remaining 22 patients initially received porcine insulin. The trial lasted for 12 weeks, with crossover to the other type of insulin after six weeks.
Blind labelling of insulin was done by the hospital pharmacy staff. The semisynthetic human insulin and highly purified porcine insulins used were Insulatard (a protamine insulin, Nordisk) and Velosulin (a soluble insulin, Nordisk) (all 100 units/ml). The Data were expressed as means (standard deviations), medians (ranges), or proportions (number in numerator). The computer programs SAS-PC and EGRET were used.
Results
Twenty two patients had normal results to autonomic cardiovascular function tests (duration of diabetes (8 4) years), 17 patients had one or more abnormal heart rate test result (duration of diabetes 16-7 (9 5) years), and five patients had both abnormal heart rate and blood pressure test results (duration of diabetes 25-6 (6 5) years; p=003 by analysis of variance). There were no significant differences in the baseline characteristics between patients who received human insulin first and those who received porcine insulin first ( (2 7) 16 6 2-87 (0 32) [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] (1-20) A total of 12 582 blood glucose measurements were performed (6150 during treatment with human insulin and 6432 during treatment with porcine insulin). In all 11 932 were routine measurements performed either in the morning after fasting, before lunch or dinner, or at bedtime. Table II shows the mean blood glucose concentrations calculated from these routine measurements. There were no significant differences between the two treatment periods. Haemoglobin Alc and fructosamine concentrations and insulin doses were similar during the two treatment periods.
Of 6150 blood glucose measurements performed during treatment with human insulin, 417 (6 8%) were ,s2-8mmol/l as compared with 510 (7 9% Table III gives the frequencies ofsymptoms recorded during treatment with human insulin and porcine insulin. In the analysis based on questionnaires there were statistically significant differences between the treatment for lack of concentration, confusion, and restlessness which were all more common during treatment with human insulin. The difference was most pronounced for lack of concentration, which was recorded in 123 (53%) episodes of hypoglycaemia with human insulin but only 90 (35%) episodes with porcine insulin (p<0-0001). Analysis of symptom frequencies by patients rather than by questionnaire confirmed the differences between the two types of insulin for lack of concentration, confusion, and restlessness. Furthermore, there was a trend toward fewer episodes of hunger, tremor, and sweating during treatment with human insulin. Analysed either way, lack of concentration, restlessness, and tremor were the three most commonly reported symptoms treatment with human insulin whereas tremor, sweating, and restlessness were the symptoms most commonly reported with porcine insulin. Compared with an absence of neuroglycopenic symptoms the odds ratio obtained from logistic regression for one neuroglycopenic symptom with human insulin as compared with porcine insulin was 1-7 (95% confidence interval 1-03 to 2 7), for two neuroglycopenic symptoms 2-1 (1-3 to 3-5), for three 2-8 (1P5 to 5 3), and for four [3] [4] [5] [6] [7] [8] [9] (1P7 to 9 1). No such trend was evident for autonomic symptoms.
There were no significant treatment period interactions,12 with probability values ranging from 0 24 for visual disturbance to 0-98 for tremor. Results were not materially altered when the first week or the first two weeks of each treatment period were excluded from analysis. Therefore, no important carryover effect was present.
AUTONOMIC FUNCTION AND GLYCAEMIC CONTROL
There was no significant influence of autonomic function on the total number of autonomic or neuroglycopenic symptoms. Tighter glycaemic control, however, as indicated by lower fructosamine concentrations, was associated with a greater number of neuroglycopenic symptoms (p=0002 by analysis of variance), while the number of autonomic symptoms was similar.
RECURRENT SEVERE HYPOGLYCAEMIA
To investigate which symptoms may be helpful for recognition of hypoglycaemia and which may impair awareness the 12 patients who had had two or more episodes of hypoglycaemic coma during the preceding three years were compared with the remaining 32 patients. Table IV shows that patients with a history of recurrent hypoglycaemic coma were older and had a longer duration of diabetes, lower fructosamine and haemoglobin Ale concentrations, and a higher prevalence ofabnormal autonomic function test results. These differences were not significant except for the The allocation of symptoms into the categories "autonomic" and "neuroglycopenic" needs to be considered. An earlier study showing that neuroglycopenic symptoms were more common and autonomic symptoms less common with human insulin was criticised because restlessness was classified as a neuroglycopenic symptom. 4 It was argued that restlessness was a manifestation of autonomic stimulation. Because the differences observed between human and porcine insulin were no longer significant when this symptom was allocated to the autonomic category, the results were said to be inconclusive. 4 The allocation of hunger is also controversial. In one standard textbook hunger is classified as a neuroglycopenic symptom in one chapter'6 and as an autonomic symptom in another.7 Other major textbooks consider hunger as an autonomic symptom and restlessness as a neuroglycopenic symptom.'7 1 This view is supported by the findings of the present study. Sweating, tremor, and hunger tended to occur together, suggesting that a common aetiology, probably stimulation of the autonomic nervous system, underlies them. On the other hand, lack of concentration, confusion, restlessness, and visual disturbance were associated, probably because neuroglycopenia plays a major part in their pathogenesis. The importance of the two categories of symptoms stems from the fact that neuroglycopenic symptoms are strongly associated with an increased risk ofrecurrent severe hypoglycaemia_, and conversely, autonomic symptoms may protect against severe hypoglycaemia.
Does the pattern of symptoms observed with human insulin impair the recognition of hypoglycaemia, and is it therefore of concern from a clinical point of view? The incidence of hypoglycaemic coma (in one patient with human insulin and in two with porcine insulin) does not support this suggestion. This trial was not, however, designed to study the incidence of severe hypoglycaemia-a far greater sample size would be needed for that purpose.'9 Abrupt onset of hypoglycaemia was more common with human insulin, and significantly fewer hypoglycaemic episodes were recorded with human insulin, suggesting a less reliable recognition of hypoglycaemia. The strongest evidence that the pattern of symptoms with human insulin may be of concern, however, comes from the fact that neuroglycopenic symptoms were associated with a history of hypoglycaemic coma. In our case-control study we found that the risk of severe hypoglycaemia was indeed increased in patients transferred to human insulin during the period it was introduced into treatment. ' The differences betwen human insulin and porcine insulin may be of particular concern in patients with recurrent severe hypoglycaemia in whom a change to human insulin could exacerbate an existing tendency to neuroglycopenia. The factors associated with recurrent severe hypoglycaemia were longer duration of diabetes, higher prevalence of autonomic dysfunction, and tighter glycaemic control. Intensive insulin treatment leading to near normal blood glucose control is an established risk factor for severe hypoglycaemia. 20 The importance of autonomic neuropathy as an independent risk factor, however, has been questioned.2"
The pathophysiological mechanism leading to the observed differences in the pattern of symptoms is unclear. Interestingly, the alterations produced by human insulin are similar to those which are observed in patients with tight glycaemic control. It has been shown that intensive treatment which reduces haemoglobin Alc concentration may impair glucose counterregulation. The In conclusion, treatment with human insulin is associated with a pattern ofsymptoms ofhypoglycaemia which may increase the risk of severe hypoglycaemia.
Human insulin in general offers no advantage over highly purified animal insulins.3 Patients should therefore be transferred to human insulin onlv when there is a medical indication, under a doctor's guidance, and after having been informed that a change in symptoms ofhypoglycaemia could occur. As advocated previously,"' a large randomised clinical trial is now needed to establish definitively whether there is an increased risk of severe hypoglycaemia associated with transfer to human insulin. (GH) through the right internal jugular vein. The cannula was connected to a bedside saline manometer, and free antegrade flow of saline and retrograde flow of blood was established by raising and lowering the reservoir. In all cases the column of saline fell rapidly on opening the tap to the patient and at the equilibration point the meniscus was observed to move with respiration. 
